Six Cases of Esophagogastric Junctional Cancer Successfully Treated with Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy(NAC)is prescribed for resectable esophagogastric junctional cancer on the basis of esophageal invasion length, lymph node metastasis, and pathological diagnosis. Due to a lack of consensus in Japan, however, discussion regarding its use is necessary. This study comprised 6 p...

Full description

Saved in:
Bibliographic Details
Published in:Gan to kagaku ryoho Vol. 50; no. 13; p. 1685
Main Authors: Hiroi, So, Fukuda, Shintaro, Yamahata, Yuto, Otani, Takahiro, Tada, Tetsuya, Hirukawa, Hiroshi
Format: Journal Article
Language:Japanese
Published: Japan 01.12.2023
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Esophageal Neoplasms - surgery
Esophagogastric Junction - pathology
Esophagogastric Junction - surgery
Female
Gastrectomy
Humans
Male
Neoadjuvant Therapy
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
ISSN:0385-0684
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neoadjuvant chemotherapy(NAC)is prescribed for resectable esophagogastric junctional cancer on the basis of esophageal invasion length, lymph node metastasis, and pathological diagnosis. Due to a lack of consensus in Japan, however, discussion regarding its use is necessary. This study comprised 6 patients who underwent surgical resection after receiving NAC in our department from 2018 to 2022. All the patients were male, with a median age of 67 years. Three patients underwent SP therapy, 2 received SOX therapy, and 1 received both SOX and HER therapy. A total gastrectomy was performed in 3 cases, a fundectomy in 1 case, and a subtotal esophagectomy with gastric tube reconstruction in 2 cases. The histological types were tub2 in 3 cases; and tub1 plus pap, por1 plus pap, and NEC in 1 case each, respectively. One case was ypStage ⅠA, 2 cases were ⅠB, 1 was ⅡA, 1 was ⅡB and 1 was pCR. Currently, all the patients remain alive and without recurrence. NAC has, therefore, been demonstrated to be an effective therapeutic strategy for esophagogastric junctional cancer in this study. However, further research with a larger sample size is required.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0385-0684